Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Puma

- PMLiVE

Merck cuts MK-3475 deals with Pfizer, Amgen and Incyte

Sees combination potential for cancer prospect

- PMLiVE

Pfizer partners with Siemens on diagnostics

Will develop companion diagnostics to support clinical studies

- PMLiVE

NIH forges $230m research alliance with pharma

Brings 10 pharma companies together to speed up research in Alzheimer’s, diabetes and arthritis

- PMLiVE

A new option for people with HIV

ViiV Healthcare's dolutegravir could capture a significant share of the HIV market and may have blockbuster potential

- PMLiVE

EMA brings transparency to its committee proceedings

Publishes meeting minutes of CHMP and two other advisory groups

- PMLiVE

Pfizer beats earnings estimates as new products grow

Lyrica, Inlyta and Xalkori help offset generic competition

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

- PMLiVE

Blow to Pfizer as dacomitinib fails in lung cancer trials

Unable to demonstrate improved survival in patients

Novartis building

CHMP denies Novartis’ heart failure drug

Panel refuses to recommend serelaxin for use in EU

- PMLiVE

GSK’s diabetes drug among CHMP recommendations

EMA committee also backs drugs from Bayer, Takeda and Linepharma France

Novartis building

CHMP backs Xolair for severe hives

Novartis set to expand indications for asthma drug

- PMLiVE

ViiV wins European approval for Tivicay

HIV treatment licensed in combination with other anti-retroviral drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links